RxDoctor Payments Data

Jose Sanchez Mendiola, MD

Plastic Surgery within the Head & Neck · Carolina, PRNPI 1952378341

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Sanofi at 49.6% of the total. Reporting peaked in 2022 at $527 and has fallen 66.3% since, to $177 in 2025.

$1,690in general payments, 2019–2025

Across 29 payments — averaging $58.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$838
  • GSK$250
  • Takeda Pharmaceuticals U.S.A., Inc.$241
  • Sanofi-aventis U.S. LLC$133
  • Merck$96
  • Intersect ENT, Inc.$86
  • plus $45 from 2 others

What the payments were for

  • Food & beverage$1,65698%
  • Education$342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few plastic surgery within the head & neck providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$24,384
Medicare patients
76
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab65$246,288
Azelastine Hcl869$22,932
Famotidine1,621$14,045
Montelukast Sodium1,034$10,749
Fluticasone Propionate593$10,503
Levocetirizine Dihydrochloride786$8,907
Pantoprazole Sodium949$7,265
Ofloxacin116$6,016
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav117$2,707
Mometasone Furoate122$2,428
Sucralfate15$2,209
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort27$2,001
MupirocinMupirocin Calcium19$1,821
Gentamicin Sulfate52$1,752
Diclofenac Potassium90$1,659

Paid to pharmacies, not to this prescriber.

Other plastic surgery within the head & neck in Carolina

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →